SLAMF7 Expression serves as an inclusion eligibility criterion in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials that contain SLAMF7 Expression as an inclusion criterion, 2 are phase 1 (1 open).
Trials with SLAMF7 Expression in the inclusion eligibility criteria most commonly target multiple myeloma .
Cyclophosphamide, fludarabine, cs1-car t therapy, and chimeric antigen receptor t-cells are the most frequent therapies in trials with SLAMF7 Expression as an inclusion criteria .
Significance of SLAMF7 Expression in Diseases
Multiple Myeloma +
SLAMF7 Expression is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 1 is open and 1 is closed. Of the trials that contain SLAMF7 Expression and multiple myeloma as inclusion criteria, 2 are phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.